TIDMEVG

RNS Number : 1496I

Evgen Pharma PLC

07 August 2019

7 August 2019

Evgen Pharma plc

("Evgen Pharma" or "the Company")

Grant of further European patent covering composition of SFX-01

Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces the grant of further intellectual property rights in Europe pertaining to the novel composition, SFX-01.

The newly granted patent leads with a product claim covering "a composition comprising a complex of sulforaphane and alpha-cyclodextrin". Composition-of-matter patents have already been granted in the USA and other territories. Furthermore, patents in Europe, the US and other territories relating to the method of production have also been granted.

Details of the European patent announced today, numbered EP3354267 and entitled Stablilized Sulforaphane, can be viewed at this link:

https://register.epo.org/application?number=EP18162130&lng=en&tab=doclist

Exclusive worldwide rights to the patent are held by Evgen Pharma under the terms of a licence agreement with PharmAgra Labs Inc., the US laboratory that invented SFX-01.

Steve Franklin, CEO of Evgen Pharma, said: "We are delighted by the grant of this important patent in Europe. This patent has broad claims relating to the composition of the novel drug substance, SFX-01, and as such represents a material development for the Company. It further expands the strength and depth of our intellectual property position across all the key territories with regard to the composition of the product and method of manufacture. The overall intellectual property position around SFX-01 and novel analogues has matured into an impressive patent estate, asserting our exclusive position around this new class of pharmaceutical."

Enquiries:

 
 Evgen Pharma plc www.evgen.com                                           via Walbrook 
 Dr Stephen Franklin, CEO 
 Richard Moulson, CFO 
 
 finnCap www.finncap.com                                          +44 (0) 20 7220 0500 
 Geoff Nash / Teddy Whiley (Corporate 
  Finance) 
 Alice Lane, Manasa Patil (ECM) 
 
 WG Partners LLP                                                  +44 (0) 20 3705 9330 
 Nigel Barnes / Claes Spång 
 
 Walbrook PR                              +44 (0)20 7933 87870 or evgen@walbrookpr.com 
                                                     +44 (0)7980 541 893 / +44 (0)7876 
 Paul McManus / Anna Dunphy                                                    741 001

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.

The Company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.

For further information, please visit: www.evgen.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCUGUCARUPBGAQ

(END) Dow Jones Newswires

August 07, 2019 02:00 ET (06:00 GMT)

Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Giu 2024 a Lug 2024 Clicca qui per i Grafici di Evgen Pharma
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Lug 2023 a Lug 2024 Clicca qui per i Grafici di Evgen Pharma